Clients
Selection of current and past services delivered to clients
Strategic consultancy
- In-licencing: epilepsy, clinical-stage company, UK, 2025
- Acute ischaemic stroke (AIS), mid-sized pharma company, EU, 2025 and ongoing
- Multiple sclerosis (MS), knowledge aggregator, UK, 2024
- In-licencing: AIS and traumatic brain injury (TBI), mid-sized pharma company, EU, 2023
- Paediatric development plans (PSP, PIP) in MS and AIS, multiple companies, EU, EFTA, 2022 and ongoing
- MS, consensus task force, 2019 – 2022
- MS, clinical-stage company, US, 2019 and ongoing
- MS, major pharma company, US, 2019
- MS, major pharma company, EU, 2016 – 2019
- Epilepsy, mid-sized pharma company, EU, 2018
- Paediatric epilepsy, mid-sized pharma company, EU, 2015 - 2016
- In-licencing, neuroendocrine tumour, mid-sized pharma company, EU, 2014 - 2015
- Biosimilar in MS, mid-sized pharma company, EU, 2010 – 2017
- Cognitive disorder, CRO and start-up company, EU, 2014
- Neurodegeneration in MS, major pharma company, MENA region, 2014
- Liposomal drug delivery to the brain, start-up company, EU, 2014
- Follow-on compound in MS, mid-sized pharma company, EU, 2012 – 2013
- In-licencing, biosimilar in MS, mid-sized pharma company, EU, 2012 – 2013
- Translational project in spinal-cord injury, bank, EU, 2011
Interim management at global level
- MS Phase I and III, major pharma company, EFTA region, 2020 – 2025
- MS Phase IIIb and managed access, major pharma company, EFTA region, 2017 – 2018
- MS Phase III, major pharma company, EFTA region, 2015 – 2016
- MS Phase II, major pharma company, EFTA region, 2015
- Fragile X syndrome Phase III, major pharma company, EFTA region, 2014 – 2015
- MS Phase II, major pharma company, EFTA region, 2009 – 2010
Member of scientific Advisory Boards
- AIS, mid-sized pharma company, EU, 2025
- MS, clinical-stage company, US, 2019 and ongoing
- MS, major pharma company, EU, 2016 - 2019
- Acute neurological condition, start-up company, EU, 2014
- Neuro-ophthalmology, major pharma company, EFTA region, 2012
- MS, mid-sized pharma company, EU, 2010 – 2012
- MS, major pharma company, EFTA region, 2010
Member of Study Steering Committees
- Phase II and Phase III in MS, clinical-stage company, US, 2019 and ongoing
- Long-term follow-up study, major pharma company, EFTA region, 2014 – 2017
- Global biosimilar study, mid-sized pharma company, EU, 2011 – 2015
Speaker at scientific satellite events
- MS, major pharma company, EU, 2016 - 2019
Medical expertise in neurology, neuro-ophthalmology, immunology, and stroke
- Major CRO, EU, 2017 - 2019
- Major pharma company, EFTA region, 2015 - 2018
- Mid-sized pharma company, EU, 2014 – 2015
- Mid-sized CRO, EU, 2014
- Major pharma company, EFTA region, 2009 – 2014
Scientific intelligence in neurological indications
- Mid-sized pharma company, EU, 2012 – 2014
- Mid-sized pharma company, EU, 2012 – 2013
Coaching and training of employees in drug development and multiple sclerosis
- Major pharma company, EFTA region, 2020 – 2025
- Major pharma company, EFTA region, 2018
- Major pharma company, EFTA region, 2015 – 2016
- Major pharma company, EFTA region, 2012 – 2014
- Mid-sized pharma company, EU, 2013
Expertise for legal proceedings
- Intellectual property proceedings in several EU and EFTA countries, major pharma company, US, 2022 and ongoing